Calypso Medical Technologies, Inc.

October 20, 2010 – The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a system designed to automate the response to organ motion during prostate cancer radiotherapy. The Calypso System, by Calypso Medical Technologies, could help decrease the side effects associated with prostate radiotherapy, such as bowel and bladder incontinence and sexual dysfunction.

June 16, 2010 -- Dynamic EdgeT Gating Technology, the latest innovation of the Calypso System from Calypso Medical Technologies Inc., allows therapists to set motion thresholds which disable radiation delivery if the targeted tissue moves outside the preset threshold. The technology will be demonstrated at the 52nd Annual Meeting of the American Association of Physicists in Medicine, July 18-21.

November 2, 2009 - Calypso Medical Technologies, Inc. today announced Calypso’s real-time tracking technology is included in 36 scientific presentations and posters at the 51st Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), now underway at McCormick Place in Chicago.

Known as GPS for the Body technology, the Calypso System utilizes miniature implanted Beacon transponders to provide precise, continuous, real-time information about the location of the tumor target during external beam radiation therapy. Any movement by the patient, including internal movement of the tumor, has the potential to compromise treatment accuracy.

June 18, 2009 - Calypso Medical Technologies announced the publication of three new studies investigating the role of the Calypso 4D Localization System in guiding immediate adjustments to radiation delivery in response to tumor motion, a concept known as real-time adaptive radiation treatment.